New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
10:56 EDTCYTK, VJET, DATA, GRPN, CTRPOptions with increasing implied volatility: CYTK VJET DATA GRPN CTRP
News For CYTK;VJET;DATA;GRPN;CTRP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
17:25 EDTGRPNGroupon initiated with a Buy at Brean Capital
Subscribe for More Information
10:00 EDTCTRPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTCTRPCtrip.com initiated with a Buy at Citigroup
Subscribe for More Information
October 20, 2014
16:24 EDTCTRPPriceline raises stake in Ctrip.com to 7.9% from 6.88%
16:14 EDTGRPNGroupon updates IPhone app to include Apple Pay
Subscribe for More Information
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
October 13, 2014
09:23 EDTDATAHP could buy lower valuation company, says Bernstein
Subscribe for More Information
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information
October 10, 2014
16:22 EDTCTRPPriceline raises stake in Ctrip.com to 6.88% from 5.84%
Subscribe for More Information
10:01 EDTGRPNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:00 EDTGRPNOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTGRPNGroupon downgraded to Sell from Equal Weight at Evercore

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use